TYK Medicines (HKSE:02410) ROE % Adjusted to Book Value: -7.47% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02410 TYK Medicines Inc HKSE:02410
7 GF Score
Price HK$6.81
! 3 Warning Signs
View Full Analysis

What is TYK Medicines ROE % Adjusted to Book Value?

TYK Medicines HKSE:02410 -4.08% 7 ROE % Adjusted to Book Value is -7.47% as of Dec. 2025. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

TYK Medicines's ROE % for the quarter that ended in Dec. 2025 was -117.28%. TYK Medicines's PB Ratio for the quarter that ended in Dec. 2025 was 15.69. TYK Medicines's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -7.47%.

TYK Medicines ROE % Adjusted to Book Value Related Terms

TYK Medicines ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for TYK Medicines's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TYK Medicines ROE % Adjusted to Book Value Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -5.16

TYK Medicines Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 0.00 0.00 -2.67 -7.47

HKSE:02410 vs VRTX, REGN, RVMD: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, TYK Medicines's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TYK Medicines ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TYK Medicines's ROE % Adjusted to Book Value falls into.


HKSE:02410
7GF Score
TYK Medicines Inc HKSE:02410
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TYK Medicines ROE % Adjusted to Book Value Calculation

TYK Medicines's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-81.02% / 15.69
=-5.16%

TYK Medicines's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-117.28% / 15.69
=-7.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -7.47% mean?
TYK Medicines (HKSE:02410) has a ROE % Adjusted to Book Value of -7.47% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TYK Medicines and its competitors.
Is TYK Medicines' ROE % Adjusted to Book Value too high?
TYK Medicines' current ROE % Adjusted to Book Value is -7.47%. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' ROE % Adjusted to Book Value compare to VRTX and REGN?
TYK Medicines' ROE % Adjusted to Book Value of -7.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TYK Medicines and its competitors. TYK Medicines's current ROE % Adjusted to Book Value is -7.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current ROE % Adjusted to Book Value of -7.47%. The current ROE % Adjusted to Book Value is -7.47%. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current ROE % Adjusted to Book Value is -7.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TYK Medicines Business Description

Address No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score

Get the complete analysis for HKSE:02410

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.81
Price